Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 9/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233464 | 0.93 | MAPT (0.46) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL8874014 | 0.75 | EGFR (0.58) | TDO2EGFRPIK3CDPIK3CA | |
| SCHEMBL12445185 | 0.75 | MAPT (0.65) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL9039580 | 0.73 | EGFR (0.41) | TDO2EGFRPIK3CDPIK3CA | |
| SCHEMBL31514041 | 0.73 | QPCT (0.51) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL5255547 | 0.73 | HPGDS (0.44) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL14511179 | 0.72 | MAPT (0.68) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL30035692 | 0.70 | GRIN2D (0.44) | MAPTKDM4EALDH1A1BLMTDO2 | |
| SCHEMBL6017066 | 0.70 | KDM4E (0.44) | MAPTKDM4EALDH1A1TDO2EGFR | |
| SCHEMBL10423642 | 0.70 | NPC1 (0.50) | MAPTKDM4EALDH1A1APEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2022-10-18 | — | — | US | disclosed |
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2020-10-08 | — | — | US | disclosed |
| US-8778643-B2 | Methods for increasing lipid levels and producing triacylglycerols in algae | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130273620-A1 | METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-17 | — | — | US | disclosed |
| EP-1706409-A1 | COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005068466-A1 | COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2005-07-28 | — | — | WO | disclosed |
| US-6127541-A | 8-((DISUBSTITUTED AMINO)BENZYLAMINO)-2,3-DIHYDRO-1H-IMIDAZO(4,5-G)QUINAZOLINE-(2-THIONE OR 2-ONE); SELECTIVE CYCLIC GUANOSINE 3',5' MONOPHOSPHATE (CGMP)--SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORY ACTIVITY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-0863144-A1 | IMIDAZOQUINAZOLINE DERIVATIVES | Kyowa Hakko Co., Ltd. (JP) | 1998-09-09 | — | — | EP | disclosed |
| US-5661147-A | CYCLIC GUANOSINE MONOPHOSPHATE-SPECIFIC PHOSPHODIESTERASE INHIBITOR; TREATING CARDIOVASCULAR DISORDER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-08-26 | — | — | US | disclosed |
| EP-0758653-A1 | IMIDAZOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-02-19 | — | — | EP | disclosed |
| WO-1996029331-A1 | IMIDAZOQUINAZOLINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | DR. KARL THOMAE GMBH (DE) | 1996-09-26 | — | — | WO | disclosed |
| EP-0668280-A1 | IMIDAZOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | IDO2, IDO1, TPH2 | MAPT 1854/4885KDM4E 338/4885ALDH1A1 399/4885 |
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | IDO1, IDO2, TPH2 | MAPT 2112/4885KDM4E 369/4885ALDH1A1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.